CA3103847A1 - Combinations of ripk1- and ikk-inhibitors for the prevention or treatment of immune diseases - Google Patents

Combinations of ripk1- and ikk-inhibitors for the prevention or treatment of immune diseases Download PDF

Info

Publication number
CA3103847A1
CA3103847A1 CA3103847A CA3103847A CA3103847A1 CA 3103847 A1 CA3103847 A1 CA 3103847A1 CA 3103847 A CA3103847 A CA 3103847A CA 3103847 A CA3103847 A CA 3103847A CA 3103847 A1 CA3103847 A1 CA 3103847A1
Authority
CA
Canada
Prior art keywords
inhibitor
ripki
ikk
treatment
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3103847A
Other languages
English (en)
French (fr)
Inventor
Manolis Pasparakis
Nikos Oikonomou
Apostolos Polykratis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet zu Koeln
Original Assignee
Universitaet zu Koeln
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet zu Koeln filed Critical Universitaet zu Koeln
Publication of CA3103847A1 publication Critical patent/CA3103847A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3103847A 2017-12-07 2018-12-07 Combinations of ripk1- and ikk-inhibitors for the prevention or treatment of immune diseases Pending CA3103847A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17205864.6A EP3494994A1 (en) 2017-12-07 2017-12-07 Combinations of ripk1- and ikk-inhibitors for the prevention or treatment of immune diseases
EP17205864.6 2017-12-07
PCT/EP2018/084055 WO2019110832A1 (en) 2017-12-07 2018-12-07 Combinations of ripk1- and ikk-inhibitors for the prevention or treatment of immune diseases

Publications (1)

Publication Number Publication Date
CA3103847A1 true CA3103847A1 (en) 2019-06-13

Family

ID=60629504

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3103847A Pending CA3103847A1 (en) 2017-12-07 2018-12-07 Combinations of ripk1- and ikk-inhibitors for the prevention or treatment of immune diseases

Country Status (7)

Country Link
US (1) US20200383995A1 (https=)
EP (2) EP3494994A1 (https=)
JP (1) JP7527639B2 (https=)
CN (1) CN111670049A (https=)
CA (1) CA3103847A1 (https=)
MX (1) MX2020007036A (https=)
WO (1) WO2019110832A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021046515A1 (en) * 2019-09-06 2021-03-11 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase i for the treatment of disease
IL291665B2 (en) 2019-09-27 2025-07-01 Univ Texas Inhibitors of receptor interacting protein kinase i for the treatment of disease
JP2023502514A (ja) 2019-11-26 2023-01-24 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム 疾患の処置のための受容体相互作用プロテインキナーゼｉの阻害剤
EP4209213A1 (en) * 2022-01-05 2023-07-12 Universität zu Köln Signalling-pathway inhibitor combinations for use in the treatment of cancer diseases
WO2024170776A1 (en) 2023-02-17 2024-08-22 Universität Zu Köln Triple kinase inhibition for the treatment of type i interferon response associated disorders
CN119064582B (zh) * 2024-09-02 2025-05-27 南方医科大学南方医院 RIPK1 O-GlcNAc糖基化抑制剂在制备增强肾细胞癌舒尼替尼敏感性药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03006817A (es) * 2001-02-01 2003-11-13 Bristol Myers Squibb Co Metodo de tratamiento de enfermedades inflamatorias e inmunes usando inhibidores de la ikb cinasa (ikk).
JP2009539865A (ja) * 2006-06-06 2009-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換３−アミノ−チエノ［２，３−ｂ］ピリジン２−カルボン酸アミド化合物及び製造方法及びそれらの使用
ES2555160B1 (es) * 2014-06-24 2016-10-25 Aptus Biotech, S.L. Aptámeros específicos de TLR-4 y usos de los mismos
EP3017825A1 (en) * 2014-11-06 2016-05-11 Ludwig-Maximilians-Universität München An inhibitor of the RIPK1-dependent necrosis pathway and a pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
EP3720493C0 (en) 2024-07-24
EP3720493B1 (en) 2024-07-24
WO2019110832A1 (en) 2019-06-13
EP3720493A1 (en) 2020-10-14
CN111670049A (zh) 2020-09-15
JP7527639B2 (ja) 2024-08-05
MX2020007036A (es) 2020-12-03
JP2021505611A (ja) 2021-02-18
US20200383995A1 (en) 2020-12-10
EP3494994A1 (en) 2019-06-12

Similar Documents

Publication Publication Date Title
EP3720493B1 (en) Combinations of ripk1- and ikk-inhibitors for the prevention or treatment of immune diseases
Huang et al. A review of the role of cav-1 in neuropathology and neural recovery after ischemic stroke
US12239686B2 (en) Immune checkpoint inhibitor combinations
AU2019338535A1 (en) Methods and compositions for treating cancer using mRNA therapeutics
JP6403240B2 (ja) シータデフェンシンによる炎症性プロテアーゼの遮断
KR101749138B1 (ko) 신경질환 예방 또는 치료를 위한 aimp2-dx2를 포함하는 약학 조성물 및 이의 용도
CA2999390A1 (en) Treatment of neurodegenerative diseases
US7892539B2 (en) Modulation of an innate immune response by altering TRIAL-R signaling
JP2018506506A (ja) 神経変性障害
JP2019501183A (ja) 調節ｔ細胞媒介性疾患の予防または治療用薬学的組成物
WO2014022427A1 (en) Inhibition of rho and or rock and cell transplantation
EP1278537A2 (en) Methods for stimulating nervous system regeneration and repair by regulating arginase i and polyamine synthesis
AU2001259453A1 (en) Methods for stimulating nervous system regeneration and repair by regulating arginase 1 and polyamine synthesis
US7358224B2 (en) Class III SLRP agonists for the reduction of blood vessel formation
US20210069189A1 (en) Treatment of neurodegenerative diseases
KR102259058B1 (ko) Herpud1 억제제를 유효성분으로 포함하는 결핵의 예방 또는 치료용 약학 조성물
KR101917419B1 (ko) Ｃｒｉｆ１을 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 조성물
WO2026056985A1 (zh) 抑郁症的治疗方法和药物组合物
KR20150123175A (ko) Dab2 유전자가 과발현된 수지상 세포를 포함하는 자가면역질환 예방 또는 치료용 약제학적 조성물
WO2020022518A1 (ja) 筋萎縮性側索硬化症を含む神経疾患の予防剤及び／又は治療剤
Dunlop et al. Demonstration of stem cell inhibition and myeloprotective effects of

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231115

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - SMALL

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241128

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241128

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241128

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241203

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250403

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250407

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250717

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250717

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - SMALL

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251128

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251128

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260408